SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?


To: stockdoc77 who wrote (50134)2/7/2019 11:16:47 PM
From: ladyPI3 Recommendations

Recommended By
immuapproval
mrc758
plhky3465

  Read Replies (1) | Respond to of 63285
 
I think the best decision they could make is to sell the company, sooner rather than later.



To: stockdoc77 who wrote (50134)2/8/2019 6:10:30 AM
From: patlawche11  Read Replies (1) | Respond to of 63285
 
>and that the P3 trial doesn't report a negative result, which destroys the company<

Isn't the Ascent P3 an open-label, randomized trial. If so, wouldn't IMMU have a sense of whether or not 132 was showing improved efficacy over the control (maybe not with full statistical analysis) well ahead of 2020, especially if they are planning or allowed an interim look, and to use this information for business purposes?